Puma biotechnology announces publication of results from phase ii summit trial evaluating neratinib in her2-mutant, metastatic cervical cancers

Puma biotechnology's p 2 summit trial results of neratinib in her2-mutant, metastatic cervical cancers were published online in gynecologic oncology.

AXDX Ratings Summary

AXDX Quant Ranking